BR112022013944A2 - Agente profilático ou terapêutico para demência - Google Patents

Agente profilático ou terapêutico para demência

Info

Publication number
BR112022013944A2
BR112022013944A2 BR112022013944A BR112022013944A BR112022013944A2 BR 112022013944 A2 BR112022013944 A2 BR 112022013944A2 BR 112022013944 A BR112022013944 A BR 112022013944A BR 112022013944 A BR112022013944 A BR 112022013944A BR 112022013944 A2 BR112022013944 A2 BR 112022013944A2
Authority
BR
Brazil
Prior art keywords
dementia
prophylatic
therapeutic agent
agent
rgma
Prior art date
Application number
BR112022013944A
Other languages
English (en)
Inventor
Itokazu Takahide
Uno Hiroki
Ishida Hirokazu
Yamashita Toshihide
Original Assignee
Univ Osaka
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Mitsubishi Tanabe Pharma Corp filed Critical Univ Osaka
Publication of BR112022013944A2 publication Critical patent/BR112022013944A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

AGENTE PROFILÁTICO OU TERAPÊUTICO PARA DEMÊNCIA. Esta invenção fornece um agente que compreende uma substância inibidora de RGMa para prevenir ou tratar demência selecionada de demência diabética e demência vascular.
BR112022013944A 2020-01-15 2021-01-15 Agente profilático ou terapêutico para demência BR112022013944A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020004403 2020-01-15
PCT/JP2021/001276 WO2021145435A1 (ja) 2020-01-15 2021-01-15 認知症の予防又は治療剤

Publications (1)

Publication Number Publication Date
BR112022013944A2 true BR112022013944A2 (pt) 2022-09-20

Family

ID=76863789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013944A BR112022013944A2 (pt) 2020-01-15 2021-01-15 Agente profilático ou terapêutico para demência

Country Status (13)

Country Link
US (1) US20230090965A1 (pt)
EP (1) EP4091633A4 (pt)
JP (1) JPWO2021145435A1 (pt)
KR (1) KR20220113794A (pt)
CN (1) CN114945385A (pt)
AR (1) AR121065A1 (pt)
AU (1) AU2021207010A1 (pt)
BR (1) BR112022013944A2 (pt)
CA (1) CA3168209A1 (pt)
IL (1) IL294769A (pt)
MX (1) MX2022008588A (pt)
TW (1) TW202140555A (pt)
WO (1) WO2021145435A1 (pt)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2568898T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
AU2005221471A1 (en) 2004-03-11 2005-09-22 Bioclues, Inc Axon regeneration promoter
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN104487455A (zh) * 2012-01-27 2015-04-01 艾伯维德国有限责任两合公司 用于诊断和治疗与神经突变性相关的疾病的组合物和方法
JP6497760B2 (ja) 2015-04-28 2019-04-10 田辺三菱製薬株式会社 ＲＧＭａ結合タンパク質及びその使用

Also Published As

Publication number Publication date
AR121065A1 (es) 2022-04-13
KR20220113794A (ko) 2022-08-16
IL294769A (en) 2022-09-01
TW202140555A (zh) 2021-11-01
AU2021207010A1 (en) 2022-08-25
MX2022008588A (es) 2022-08-10
WO2021145435A1 (ja) 2021-07-22
JPWO2021145435A1 (pt) 2021-07-22
EP4091633A4 (en) 2024-07-10
CN114945385A (zh) 2022-08-26
EP4091633A1 (en) 2022-11-23
CA3168209A1 (en) 2021-07-22
US20230090965A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
BRPI0517887A (pt) combinações de inibidores de jaks
BR112017015059A2 (pt) inibidor de proteassoma e uso
BR112018069732A2 (pt) métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
BR112022008817A2 (pt) Terapias combinadas para tratamento de câncer
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112023020182A2 (pt) Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula
BR112018001438A2 (pt) expressão de fgfr e suscetibilidade a um inibidor de fgfr
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
BR112021017820A2 (pt) Composições e métodos para modulação da atividade de complemento
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
CO2019002245A2 (es) Combinación de agonistas de fxr
CL2021002176A1 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040)
ECSP20082339A (es) Moduladores de la expresión de apol1
BR112023002225A2 (pt) Método para tratar um distúrbio mediado pela ikaros e/ou aiolos
BR112017004505A2 (pt) agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo.
PE20221410A1 (es) Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80
CO2022014499A2 (es) Moduladores de nlrp3
BR112022013944A2 (pt) Agente profilático ou terapêutico para demência
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al